26/07/2014 05:11:13 Free Membership Login

Merck News (NYSE:MRK)

DateTimeSource
Headline
07/24/20148:30AMBWMerck Initiates Phase 3 Study of Letermovir, an Investigational Antiviral for Prevention of Cytomegalovirus (CMV) Infection i...
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the first patient has been enrolled in a global Phase 3 clinical study of letermovir (MK-8228), an investigational antiviral agent. The multicenter, randomized, placebo-controlled study will evaluate the efficacy and safety of letermovir... More...>>
07/23/201412:15PMBWMerck Announces Fourth-Quarter 2014 Dividend
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.44 per share of the company’s common stock for the fourth quarter of 2014. Payment will be made on October 7, 2014, to stockholders of record at the close of business... More...>>
07/17/20148:30AMPRNUSMerck's HIV Campaign, I Design, Partners with Music Industry Promoter and HIV Advocate Maria Davis and Positive Women's Netwo...
Merck's HIV Campaign, I Design, Partners with Music Industry Promoter and HIV Advocate Maria Davis and Positive Women's Network - USA to Encourage Women Living with HIV to be "Vocal" about their Treatment "Speaking Up" is Vital, Given the Significant Impact of the Disease on Women PR Newswire WHITEHOUSE... More...>>
07/07/20143:20PMDJNNovartis Wins 'Breakthrough' Status for Leukemia Treatment
ZURICH-- Novartis AG said Monday the U.S. Food and Drug Administration designated a new leukemia treatment it is developing as a "breakthrough" therapy, giving it access to a potentially faster regulatory review process. Basel-based Novartis's CTL019 treatment, which is being tested at the University of Pennsylvania's... More...>>
06/30/20148:00AMBWMerck Announces Data from Investigational Phase 3 Study on EMEND® (aprepitant) for the Prevention of Chemotherapy-Induced Na...
Merck Planning Regulatory Submissions in the U.S. for EMEND® in Pediatric Setting Including New Suspension Formulation in Second Half of 2014 Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from a global, investigational Phase 3 study to evaluate the safety and efficacy of... More...>>
06/30/20146:00AMBWMerck’s Investigational Anti-PD-1 Antibody, Pembrolizumab, Under Regulatory Review in Europe for the Treatment of Advanced ...
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the European Medicines Agency (EMA) has accepted for review a Marketing Authorization Application (MAA) for pembrolizumab (MK-3475), the company’s investigational anti-PD-1 antibody, for the treatment of advanced melanoma. If approved... More...>>
06/30/20146:00AMBWMSD’s Investigational Anti-PD-1 Antibody, Pembrolizumab, Under Regulatory Review in Europe for the Treatment of Advanced Me...
MSD, known as Merck (NYSE:MRK) in the United States and Canada, today announced the European Medicines Agency (EMA) has accepted for review a Marketing Authorization Application (MAA) for pembrolizumab (MK-3475), the company’s investigational anti-PD-1 antibody, for the treatment of advanced melanoma. If approved by... More...>>
06/30/20146:00AMBWPembrolizumab, l'anticorpo anti-PD-1 di MSD, è sottoposto a revisione normativa in Europa per il trattamento del melanoma in...
MSD, azienda farmaceutica nota come Merck (NYSE:MRK) negli Stati Uniti e in Canada, ha annunciato in data odierna la risposta favorevole dell'Agenzia europea per i medicinali (EMA) a considerere la domanda di autorizzazione presentata dall'azienda per l'immmissione in commercio di pembrolizumab (MK-3475). Si tratta dell'anticorpo... More...>>
06/30/20146:00AMBWAnti-PD-1-Antikörper-Kandidat Pembrolizumab von MSD wird zurzeit von Zulassungsbehörde in Europa für die Behandlung des fo...
MSD, in den USA und Kanada als Merck (NYSE:MRK) bekannt, meldete heute, dass die Europäische Arzneimittel-Agentur (EMA) den Zulassungsantrag (MAA) für Pembrolizumab (MK-3475), den Anti-PD-1-Antikörper-Kandidaten des Unternehmens, für die Indikation Behandlung des fortgeschrittenen Melanoms zur Prüfung angenommen hat... More...>>
06/30/20146:00AMBWL'anticorps anti-PD-1 expérimental de MSD, le pembrolizumab, est actuellement examiné par les autorités de réglementation...
MSD, appelée Merck (NYSE : MRK) aux États-Unis et au Canada, a annoncé aujourd'hui que l'Agence européenne des médicaments (AEM) a accepté d'examiner une demande d'autorisation de mise sur le marché pour le pembrolizumab (MK-3475), l'anticorps anti-PD-1 expérimental de la société, dans le cadre du traitement... More...>>
06/26/20148:00AMPRNUSAward-Winning Actress S. Epatha Merkerson and Merck Challenge African Americans with Type 2 Diabetes to Get to Their Goals
Award-Winning Actress S. Epatha Merkerson and Merck Challenge African Americans with Type 2 Diabetes to Get to Their Goals Merkerson Visits Washington, D.C. on June 26 With America's Diabetes Challenge: Get to Your Goals Program PR Newswire WHITEHOUSE STATION, N.J., June 26, 2014 WHITEHOUSE STATION, N.J., June 26, 2014... More...>>
06/23/20145:00PMBWMerck to Hold Second-Quarter 2014 Sales and Earnings Conference Call on July 29
Merck (NYSE:MRK), known as MSD outside the United States and Canada, will hold its second-quarter 2014 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Tuesday, July 29. During the call, company executives will provide an overview of Merck’s performance for the quarter... More...>>
06/23/20148:00AMBWMerck Names Michael J. Holston as Future General Counsel; Will Succeed Bruce N. Kuhlik in July 2015
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the future appointment of Michael J. Holston as general counsel, effective July 01, 2015. Holston, who will also oversee responsibility for Merck’s communications, policy and security organizations beginning July 1 of this year, will... More...>>
06/20/20147:30AMBWMerck Begins Tender Offer to Acquire Idenix
Merck (NYSE:MRK), known as MSD outside the United States and Canada, is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX). On June 09, 2014, Merck announced its intent to acquire Idenix. Upon the successful closing... More...>>
06/13/20148:00AMBWMerck Launches Global Patient Registry Supporting Expanded Commitment to Real-World Outcomes Research in Type 2 Diabetes
New Research Initiative Seeks to Identify Unmet Needs and Address Key Gaps in the Management of Type 2 Diabetes Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the launch of a global registry to evaluate the experiences and outcomes of approximately 20,000 patients with type 2 diabetes... More...>>
06/09/20145:14PMDJNMerck to Buy Idenix for $3.85 Billion -- 7th Update
By Peter Loftus Merck & Co.'s $3.85 billion deal to acquire a developer of hepatitis C drugs underscores the pharmaceutical industry's bet that improved medicines for the liver disease represent a large, long-term market opportunity. Merck agreed to acquire Idenix Pharmaceuticals Inc. for $24.50 a share in cash, more... More...>>
06/09/20144:58PMDJNMARKET SNAPSHOT: U.S. Stocks Close Up; S&P 500, Dow At Record
By Anora Mahmudova, MarketWatch NEW YORK (MarketWatch) -- The U.S. stock market ended Monday's choppy trading session slightly higher, as both the S&P 500 and Dow Jones Industrial Average closed at record levels. M&A deals between Tyson Foods Inc. and Hillshire Brands Co.; Analog Devices Inc. and Hittite Microwave... More...>>
06/09/20141:13PMDJNMerck to Buy Idenix for $3.85 Billion -- 6th Update
By Peter Loftus Merck & Co.'s $3.85 billion deal to acquire a developer of hepatitis C drugs underscores the pharmaceutical industry's bet that improved medicines for the liver disease represent a large, long-term market opportunity. Merck agreed to acquire Idenix Pharmaceuticals Inc. for $24.50 a share in cash, more... More...>>
06/09/201411:24AMDJNMerck to Buy Idenix for $3.85 Billion -- 5th Update
By Erin McCarthy Merck & Co. agreed to buy Idenix Pharmaceuticals Inc. for $3.85 billion, more than three times Idenix's value on Friday, in the latest example of the high value that drug makers are putting on hepatitis C treatments. Drug maker Merck said it would acquire Idenix for $24.50 per share in cash. Idenix... More...>>
06/09/201410:53AMDJNMARKET SNAPSHOT: U.S. Stocks Edge Higher; S&P 500 Hits Record
By Anora Mahmudova, MarketWatch NEW YORK (MarketWatch) -- The U.S. stock market edged higher on Monday, building on gains from the previous week that sent the S&P 500 and Dow Jones Industrial Average to record levels. M&A deals between Tyson Foods Inc. and Hillshire Brands Co.; Analog Devices Inc. and Hittite Microwave... More...>>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us nyse mrk140726 05:11